NDAORALFOR SUSPENSION
Approved
Sep 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLAPEN-W (cyclacillin) is an oral penicillin-class antibiotic suspension approved in 1979 for bacterial infections. The drug is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. It is formulated as an oral suspension for pediatric and adult patients requiring convenient dosing.
LOE Approaching
Product is approaching loss of exclusivity with minimal linked job openings, indicating a mature, commercially constrained portfolio.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate this product is not actively hiring; career prospects are limited to maintenance roles or transition assignments. Working on CYCLAPEN-W offers minimal growth trajectory and is best suited for consolidation or handoff strategy roles.
Brand ManagerField Sales Representative
Worked on CYCLAPEN-W at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.